Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy

Paul J. Gaglio, Maribel Rodriguez-Torres, Robert Herring, Bhupinder Anand, Terry Box, Mordechai Rabinovitz, Robert S. Brown

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Despite a rapid evolution in the treatment of Hepatitis C (HCV), response to therapy among different racial and ethnic groups is poorly characterized. Study: Three hundred and thirty HCV infected patients naive to previous therapy received induction therapy followed by every other day dosing with consensus interferon. Greater than 30% of treated patients were not white, allowing comparison of response among different races/ethnicities and genotypes. Results: An overall sustained virologic response (SVR) was achieved in 24% of white, 12% of Hispanic, and 4% of AA patients (P = 0.003 white vs. non-white). 15% of white and 13% of Hispanic Genotype 1 patients achieved an SVR; 2% of AA patients achieved an SVR (P = 0.001 AA vs. non AA). Surprisingly, an SVR of 50% and 40% was achieved by AA and White Genotype 2 patients, compared with 10% in Hispanic patients (P = 0.001). Conclusion: Significant differences in response rates to induction therapy followed by every other day dosing with consensus Interferon was observed when comparing white to non-white patients, particularly when comparing response rates by genotype. These observations reinforce the requirement that prospective studies that enroll a significant percentage of non-whites are needed to adequately characterize response rates to anti-HCV directed therapy.

Original languageEnglish (US)
Pages (from-to)599-604
Number of pages6
JournalJournal of Clinical Gastroenterology
Volume38
Issue number7
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Interferons
Genotype
Hispanic Americans
Therapeutics
Hepatitis C
Ethnic Groups
Prospective Studies
Sustained Virologic Response

Keywords

  • African American
  • Consensus interferon
  • Hepatitis C
  • Hispanic

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. / Gaglio, Paul J.; Rodriguez-Torres, Maribel; Herring, Robert; Anand, Bhupinder; Box, Terry; Rabinovitz, Mordechai; Brown, Robert S.

In: Journal of Clinical Gastroenterology, Vol. 38, No. 7, 08.2004, p. 599-604.

Research output: Contribution to journalArticle

Gaglio, PJ, Rodriguez-Torres, M, Herring, R, Anand, B, Box, T, Rabinovitz, M & Brown, RS 2004, 'Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy', Journal of Clinical Gastroenterology, vol. 38, no. 7, pp. 599-604. https://doi.org/10.1097/00004836-200408000-00012
Gaglio, Paul J. ; Rodriguez-Torres, Maribel ; Herring, Robert ; Anand, Bhupinder ; Box, Terry ; Rabinovitz, Mordechai ; Brown, Robert S. / Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. In: Journal of Clinical Gastroenterology. 2004 ; Vol. 38, No. 7. pp. 599-604.
@article{50a8e84f58024ba891262fb0daca6b53,
title = "Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy",
abstract = "Background: Despite a rapid evolution in the treatment of Hepatitis C (HCV), response to therapy among different racial and ethnic groups is poorly characterized. Study: Three hundred and thirty HCV infected patients naive to previous therapy received induction therapy followed by every other day dosing with consensus interferon. Greater than 30{\%} of treated patients were not white, allowing comparison of response among different races/ethnicities and genotypes. Results: An overall sustained virologic response (SVR) was achieved in 24{\%} of white, 12{\%} of Hispanic, and 4{\%} of AA patients (P = 0.003 white vs. non-white). 15{\%} of white and 13{\%} of Hispanic Genotype 1 patients achieved an SVR; 2{\%} of AA patients achieved an SVR (P = 0.001 AA vs. non AA). Surprisingly, an SVR of 50{\%} and 40{\%} was achieved by AA and White Genotype 2 patients, compared with 10{\%} in Hispanic patients (P = 0.001). Conclusion: Significant differences in response rates to induction therapy followed by every other day dosing with consensus Interferon was observed when comparing white to non-white patients, particularly when comparing response rates by genotype. These observations reinforce the requirement that prospective studies that enroll a significant percentage of non-whites are needed to adequately characterize response rates to anti-HCV directed therapy.",
keywords = "African American, Consensus interferon, Hepatitis C, Hispanic",
author = "Gaglio, {Paul J.} and Maribel Rodriguez-Torres and Robert Herring and Bhupinder Anand and Terry Box and Mordechai Rabinovitz and Brown, {Robert S.}",
year = "2004",
month = "8",
doi = "10.1097/00004836-200408000-00012",
language = "English (US)",
volume = "38",
pages = "599--604",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy

AU - Gaglio, Paul J.

AU - Rodriguez-Torres, Maribel

AU - Herring, Robert

AU - Anand, Bhupinder

AU - Box, Terry

AU - Rabinovitz, Mordechai

AU - Brown, Robert S.

PY - 2004/8

Y1 - 2004/8

N2 - Background: Despite a rapid evolution in the treatment of Hepatitis C (HCV), response to therapy among different racial and ethnic groups is poorly characterized. Study: Three hundred and thirty HCV infected patients naive to previous therapy received induction therapy followed by every other day dosing with consensus interferon. Greater than 30% of treated patients were not white, allowing comparison of response among different races/ethnicities and genotypes. Results: An overall sustained virologic response (SVR) was achieved in 24% of white, 12% of Hispanic, and 4% of AA patients (P = 0.003 white vs. non-white). 15% of white and 13% of Hispanic Genotype 1 patients achieved an SVR; 2% of AA patients achieved an SVR (P = 0.001 AA vs. non AA). Surprisingly, an SVR of 50% and 40% was achieved by AA and White Genotype 2 patients, compared with 10% in Hispanic patients (P = 0.001). Conclusion: Significant differences in response rates to induction therapy followed by every other day dosing with consensus Interferon was observed when comparing white to non-white patients, particularly when comparing response rates by genotype. These observations reinforce the requirement that prospective studies that enroll a significant percentage of non-whites are needed to adequately characterize response rates to anti-HCV directed therapy.

AB - Background: Despite a rapid evolution in the treatment of Hepatitis C (HCV), response to therapy among different racial and ethnic groups is poorly characterized. Study: Three hundred and thirty HCV infected patients naive to previous therapy received induction therapy followed by every other day dosing with consensus interferon. Greater than 30% of treated patients were not white, allowing comparison of response among different races/ethnicities and genotypes. Results: An overall sustained virologic response (SVR) was achieved in 24% of white, 12% of Hispanic, and 4% of AA patients (P = 0.003 white vs. non-white). 15% of white and 13% of Hispanic Genotype 1 patients achieved an SVR; 2% of AA patients achieved an SVR (P = 0.001 AA vs. non AA). Surprisingly, an SVR of 50% and 40% was achieved by AA and White Genotype 2 patients, compared with 10% in Hispanic patients (P = 0.001). Conclusion: Significant differences in response rates to induction therapy followed by every other day dosing with consensus Interferon was observed when comparing white to non-white patients, particularly when comparing response rates by genotype. These observations reinforce the requirement that prospective studies that enroll a significant percentage of non-whites are needed to adequately characterize response rates to anti-HCV directed therapy.

KW - African American

KW - Consensus interferon

KW - Hepatitis C

KW - Hispanic

UR - http://www.scopus.com/inward/record.url?scp=3242664295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242664295&partnerID=8YFLogxK

U2 - 10.1097/00004836-200408000-00012

DO - 10.1097/00004836-200408000-00012

M3 - Article

VL - 38

SP - 599

EP - 604

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 7

ER -